Abacus Medicine Sustainability Profile
Abacus Medicine, a leading player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe. Founded in 2004, the company has established itself as a key provider of parallel-imported medicines, ensuring access to high-quality pharmaceuticals at competitive prices. Abacus Medicine's core services include sourcing, distributing, and supplying a wide range of prescription medications, with a focus on efficiency and compliance with regulatory standards. The company is renowned for its commitment to quality assurance and has achieved significant milestones, including partnerships with major healthcare providers. With a strong market position, Abacus Medicine continues to innovate in the pharmaceutical supply chain, making it a trusted name in the industry. Its unique approach to parallel imports not only enhances accessibility but also contributes to cost savings for healthcare systems across its operational regions.
DitchCarbon Score
How does Abacus Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abacus Medicine's score of 40 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abacus Medicine's reported carbon emissions
In 2024, Abacus Medicine, headquartered in Denmark (DK), reported total carbon emissions of approximately 757,500 kg CO2e, comprising 216,900 kg CO2e from Scope 1 and 540,600 kg CO2e from Scope 2 emissions. The previous year, 2023, saw emissions of about 877,900 kg CO2e, with Scope 1 emissions at 235,300 kg CO2e and Scope 2 emissions at 642,600 kg CO2e. This indicates a reduction in total emissions of about 120,400 kg CO2e from 2023 to 2024. Abacus Medicine has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. The company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. The emissions data is cascaded from its parent company, Abacus Medicine A/S, reflecting the company's performance within its corporate family. As a current subsidiary, Abacus Medicine is part of a broader commitment to sustainability, although specific reduction initiatives have not been outlined.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,600 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | - | - | - | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - | - |
How Carbon Intensive is Abacus Medicine's Industry?
How Carbon Intensive is Abacus Medicine's Location?
Abacus Medicine's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abacus Medicine has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
